BR0211342A - Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns - Google Patents

Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns

Info

Publication number
BR0211342A
BR0211342A BR0211342-2A BR0211342A BR0211342A BR 0211342 A BR0211342 A BR 0211342A BR 0211342 A BR0211342 A BR 0211342A BR 0211342 A BR0211342 A BR 0211342A
Authority
BR
Brazil
Prior art keywords
mutation
virus
mutant
rabies
viral
Prior art date
Application number
BR0211342-2A
Other languages
English (en)
Inventor
Zhen Fang Fu
Original Assignee
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found filed Critical Univ Georgia Res Found
Publication of BR0211342A publication Critical patent/BR0211342A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VìRUS DE RAIVA ATENUADO COM MUTAçãO DE NUCLEOPROTEìNA NO SìTIO DE FOSFORILAçãO PARA VACINAçãO CONTRA RAIVA E TERAPIA DE GENE NA CNS". Um vírus mutante é provido o qual contem uma mutação em um sítio de fosforilação em uma ou mais das proteínas do vírus, cuja mutação faz com que o vírus seja atenuado, e por isso, uma composição de vacina aperfeiçoada pode ser produzida com o mesmo. A invenção também referese a composições de vacina que contêm os vírus mutantes, assim como a processos de indução de uma resposta imune, e de proteção de mamíferos de infecção por vírus da raiva. Também são incluídos na invenção processos de produção de vírus mutantes e proteínas virais, incluindo produção de vírus mutantes em uma célula hospedeira que produz ou mesmo super-produz uma contra-parte tipo selvagem da proteína viral mutante, que complementa as outras proteínas virais de modo que a produção da partícula viral mutante seja otimizada. A invenção também inclui aquelas células hospedeiras nas quais produção viral é otimizada, assim como composições de vacina incluindo as proteínas virais, tanto sozinhas como em combinação com os vírus intactos, e a processos de indução de uma resposta imune ou proteção de um mamífero contra infecção, usando as mesmas. Também são incluídos na invenção vetores apropriados para liberação de um gene para uma célula de um humano ou animal, assim como processo de liberação do mesmo.
BR0211342-2A 2001-07-20 2002-07-22 Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns BR0211342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33135401P 2001-07-20 2001-07-20
PCT/US2002/023108 WO2003046506A2 (en) 2001-07-20 2002-07-22 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies

Publications (1)

Publication Number Publication Date
BR0211342A true BR0211342A (pt) 2005-05-03

Family

ID=23293602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211342-2A BR0211342A (pt) 2001-07-20 2002-07-22 Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns

Country Status (17)

Country Link
US (3) US6706523B2 (pt)
EP (1) EP1434862A4 (pt)
JP (1) JP2005510249A (pt)
KR (1) KR20040029377A (pt)
CN (1) CN100346826C (pt)
AU (1) AU2002365029A1 (pt)
BR (1) BR0211342A (pt)
CA (1) CA2454397A1 (pt)
CO (1) CO5560623A2 (pt)
HR (1) HRP20040078A2 (pt)
HU (1) HUP0500722A2 (pt)
MX (1) MXPA04000589A (pt)
NZ (1) NZ531025A (pt)
PL (1) PL371967A1 (pt)
WO (1) WO2003046506A2 (pt)
YU (1) YU6304A (pt)
ZA (1) ZA200400340B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000589A (es) * 2001-07-20 2005-06-17 Univ Georgia Res Found Virus de la rabia atenuado con mutacion de nucleoproteina en el sitio de fosforilacion para vacunacion contra la rabia y terapia genetica en el snc.
US8287878B2 (en) 2004-04-09 2012-10-16 Wyeth Llc Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
CN100341571C (zh) * 2005-09-16 2007-10-10 孙介光 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用
CA2943039C (en) 2005-10-14 2018-11-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus compositions and methods
WO2007070678A2 (en) * 2005-12-14 2007-06-21 University Of Georgia Research Foundation, Inc. Rabies vaccine
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
CN102159240B (zh) * 2008-09-17 2014-12-24 美国政府健康及人类服务部，疾病控制和预防中心 基于狂犬病毒的重组免疫避孕组合物及其使用方法
US10849975B2 (en) 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
CN102205119B (zh) * 2011-04-12 2012-05-30 广州市华南农大生物药品有限公司 狂犬病灭活抗原及其制备方法
KR101479668B1 (ko) * 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
KR20170002590U (ko) 2016-01-08 2017-07-18 최문규 제조와 포장이 용이한 일회용 위생장갑
WO2017176596A1 (en) 2016-04-04 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and coronaviruses
US11155885B2 (en) 2016-05-20 2021-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time reverse transcriptase-polymerase chain reaction assay with modified probe for the diagnosis of rabies viruses and other lyssaviruses
GB201706945D0 (en) * 2017-05-02 2017-06-14 Medical Res Council Self-inactivating viral vector
US20230398201A1 (en) * 2020-11-03 2023-12-14 Thomas Jefferson University Gene shuffled lyssavirus vaccine
WO2022178307A1 (en) * 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
CN114957408B (zh) * 2021-02-24 2024-04-23 东莞博盛生物科技有限公司 一种狂犬病毒的preG改性蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
US5583735A (en) * 1994-01-18 1996-12-10 Hollingsead International, Inc. Aircraft video monitor deployment and retraction apparatus
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6719881B1 (en) * 1998-09-22 2004-04-13 Charles R. Hunter Acid colloid in a microparticle system used in papermaking
AU1386100A (en) * 1998-11-27 2000-06-19 Akzo Nobel N.V. Stable, attenuated rabies virus mutants and live vaccines thereof
MXPA04000589A (es) * 2001-07-20 2005-06-17 Univ Georgia Res Found Virus de la rabia atenuado con mutacion de nucleoproteina en el sitio de fosforilacion para vacunacion contra la rabia y terapia genetica en el snc.

Also Published As

Publication number Publication date
PL371967A1 (en) 2005-07-11
CO5560623A2 (es) 2005-09-30
KR20040029377A (ko) 2004-04-06
YU6304A (sh) 2006-08-17
MXPA04000589A (es) 2005-06-17
ZA200400340B (en) 2004-08-18
HRP20040078A2 (en) 2004-08-31
WO2003046506A3 (en) 2004-04-22
EP1434862A2 (en) 2004-07-07
US20040208900A1 (en) 2004-10-21
WO2003046506A2 (en) 2003-06-05
EP1434862A4 (en) 2005-04-06
CA2454397A1 (en) 2003-06-05
US20030099671A1 (en) 2003-05-29
CN100346826C (zh) 2007-11-07
US20070178555A1 (en) 2007-08-02
US6706523B2 (en) 2004-03-16
NZ531025A (en) 2005-08-26
JP2005510249A (ja) 2005-04-21
US7544791B2 (en) 2009-06-09
HUP0500722A2 (hu) 2005-11-28
US7419816B2 (en) 2008-09-02
CN1635905A (zh) 2005-07-06
AU2002365029A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
BR0211342A (pt) Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns
Haga et al. Genetic manipulation of human intestinal enteroids demonstrates the necessity of a functional fucosyltransferase 2 gene for secretor-dependent human norovirus infection
EA014062B1 (ru) Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
JP2007508848A (ja) ソラレン不活化ｈｉｖに基づく免疫原性組成物及びワクチンの開発方法
Charrel et al. Low diversity of Alkhurma hemorrhagic fever virus, Saudi Arabia, 1994–1999
Laver et al. Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine
BR9510590A (pt) Processo para produzir vacinas multivalentes de hemoglutinina de gripe.
Bhattacharya et al. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection
EP0173268B1 (en) A method for the preparation of a herpes simplex virus subunit vaccine
EP0171771B1 (en) A method for purification of rabies virus
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
Kallin et al. Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
Rungsa et al. Heterologous expression and mutagenesis of recombinant Vespa affinis hyaluronidase protein (rVesA2)
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
Liu et al. Concurrent gene insertion, deletion, and inversion during the construction of a novel attenuated BoHV-1 using CRISPR/Cas9 genome editing
Sugimoto et al. Algal-lytic activities encoded by Chlorella virus CVK2
BR9912626A (pt) Mutante do herpesvìrus equino, sequência de ácido nucleico, molécula de dna recombinante, célula hospedeira, vacina, e, processos para a preparação de um mutante de ehv e para atenuar geneticamente o ehv
EA037291B8 (ru) Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты)
NO20006457L (no) Vaksine-indusert hepatitt B viral stamme og anvendelser derav
RU2751485C1 (ru) Вакцина против гриппа типа А, гриппа типа B и COVID-19
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
RU2507257C1 (ru) Рекомбинантная псевдоаденовирусная частица на основе генома аденовируса человека 5 серотипа для индукции специфического иммунитета к вирусу гриппа а субтипа н1n1 и способ ее использования в качестве компонента для создания вакцины

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.